FY2025 · ended Dec 31, 2025 · Revenue $1.01M, +65.5% YoY · Filed Mar 30, 2026
60 Degrees Pharmaceuticals, Inc. (SXTP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.0 million and a net loss of $7.4 million. Free cash flow was -$7.0 million. As of Jun 30, 2026 it held $2.3 million in cash and investments and $150,030 in total debt.
Revenue (TTM)
$1.11M
+73.2% vs year-ago TTM
Net income (TTM)
$-8.11M
-3.8% vs year-ago TTM
Operating cash flow (TTM)
$-8.77M
-37.8% vs year-ago TTM
Free cash flow (TTM)
$-8.89M
-38.3% vs year-ago TTM
EPS (TTM)
$-5.44
+87.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
2.64M
+79.0% vs prior year
Net cash
$2.11M
as of Jun 30, 2026
Operating margin
-774.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SXTP (Nasdaq), SXTPW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Washington, DC
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1946563
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Revenue | $1.0M | $607,574 | $253,573 |
| Operating income | -$7.8M | -$9.7M | -$5.2M |
| Net income | -$7.4M | -$7.9M | -$3.8M |
| Diluted EPS | -$11.73 | -$74.17 | -$59.18 |
| Operating cash flow | -$6.8M | -$5.6M | -$4.5M |
| Free cash flow | -$7.0M | -$5.8M | -$4.6M |
| Total assets | $5.4M | $5.8M | $7.8M |
| Total liabilities | $2.0M | $1.8M | $3.0M |
| Stockholders' equity | $3.5M | $4.0M | $4.9M |
| Cash and investments | $2.8M | $3.4M | $20,000 |
| Total debt | $152,775 | $150,000 | $163,650 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 222 60 Degrees Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.